Annabel I. Goodwin

Hospital Rd, 2137
Concord, NSW, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 40 publications

Comparing theory-driven and intuition-based approaches to inform implementation strategies in practice: an exploratory two-arm cluster-randomized head-to-head implementation trial.

Comparing theory-driven and intuition-based approaches to inform implementation strategies in practice: an exploratory two-arm cluster-randomized head-to-head implementation trial.

Journal: JBI evidence implementation

Published: February 24, 2026

The germline POLD1 c.1420 C > A (p.Leu474Ile) variant segregates with endometrial cancer, colorectal cancer and colonic polyps demonstrating hypermutation and defective POLD1 mutational signatures.

The germline POLD1 c.1420 C > A (p.Leu474Ile) variant segregates with endometrial cancer, colorectal cancer and colonic polyps demonstrating hypermutation and defective POLD1 mutational signatures.

Journal: Familial cancer

Published: June 18, 2025

Influence of geometry, reinforcement, and sterilisation on the dimensional accuracy of additively manufactured carbon fibre-reinforced nylon composites.

Influence of geometry, reinforcement, and sterilisation on the dimensional accuracy of additively manufactured carbon fibre-reinforced nylon composites.

Journal: Scientific reports

Published: January 31, 2025

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Patient-Reported Outcomes in OlympiA: A Phase III, Randomized, Placebo-Controlled Trial of Adjuvant Olaparib in gBRCA1/2 Mutations and High-Risk Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: February 01, 2024

Platinum chemotherapy for early triple-negative breast cancer.

Platinum chemotherapy for early triple-negative breast cancer.

Journal: Breast (Edinburgh, Scotland)

Published: January 23, 2024

Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing.

Germline potential should not be overlooked for cancer variants identified in tumour-only somatic mutation testing.

Journal: Pathology

Published: November 09, 2023

Platinum-based chemotherapy for early triple-negative breast cancer.

Platinum-based chemotherapy for early triple-negative breast cancer.

Journal: The Cochrane database of systematic reviews

Published: September 08, 2023

DNA Mismatch Repair Gene Variant Classification: Evaluating the Utility of Somatic Mutations and Mismatch Repair Deficient Colonic Crypts and Endometrial Glands.

DNA Mismatch Repair Gene Variant Classification: Evaluating the Utility of Somatic Mutations and Mismatch Repair Deficient Colonic Crypts and Endometrial Glands.

Journal: Cancers

Published: September 06, 2023

An Australian mainstream genetic testing program: Clinicians views about current and future practices.

An Australian mainstream genetic testing program: Clinicians views about current and future practices.

Journal: Asia-Pacific journal of clinical oncology

Published: May 29, 2023

A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome.

A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome.

Journal: medRxiv : the preprint server for health sciences

Published: March 13, 2023

A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome.

A tumor focused approach to resolving the etiology of DNA mismatch repair deficient tumors classified as suspected Lynch syndrome.

Journal: Journal of translational medicine

Published: February 09, 2023

The clinical utility and costs of whole-genome sequencing to detect cancer susceptibility variants-a multi-site prospective cohort study.

The clinical utility and costs of whole-genome sequencing to detect cancer susceptibility variants-a multi-site prospective cohort study.

Journal: Genome medicine

Published: October 04, 2022

Showing 1-12 of 40

Last Updated: 09/26/2026